Literature DB >> 16822985

Dopamine D3 receptor agonist delivery to a model of Parkinson's disease restores the nigrostriatal pathway and improves locomotor behavior.

Jackalina M Van Kampen1, Christopher B Eckman.   

Abstract

The presence of endogenous stem cell populations in the adult mammalian CNS suggests an innate potential for regeneration and represents a potential resource for neuroregenerative therapy aimed at the treatment of neurodegenerative disorders, such as Parkinson's disease. However, it is first necessary to examine the microenvironmental signals required to activate these innate reparative mechanisms. The small molecule neurotransmitter dopamine has been shown to regulate cell cycle in developing and adult brain, and the D3 receptor is known to play an important role in dopaminergic development. Pharmacological activation of the dopamine D3 receptor has been shown to trigger neurogenesis in the substantia nigra of the adult rat brain. Here, we examined the cell proliferative, neurogenic, and behavioral effects of the dopamine D3 receptor agonist 7-OH-DPAT (7-hydroxy-N,N-di-n-propyl-2-aminotetralin) in a 6-hydroxydopamine model of Parkinson's disease. Consistent with previous findings, we observed a significant induction of cell proliferation in the substantia nigra pars compacta (SN(C)) with a time-dependent adoption of a neuronal dopaminergic phenotype in many of these cells. Indices of nigrostriatal integrity were also affected. Dopaminergic cell counts in the lesioned SN(C) recovered substantially in a time-dependent manner. Similarly, retrograde tracing revealed a restoration of striatal innervation from these cells, with evidence for projections arising from newly generated cells. Finally, we observed a substantial and persistent recovery of locomotor function in these animals. The results of these studies will further our understanding of the environmental signals regulating neurogenesis in the adult brain and could have significant implications for the design of novel treatment strategies for Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822985      PMCID: PMC6673939          DOI: 10.1523/JNEUROSCI.0837-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  39 in total

Review 1.  Dopamine Receptors and Neurodegeneration.

Authors:  Claudia Rangel-Barajas; Israel Coronel; Benjamín Florán
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 2.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

3.  Cellular repair strategies in Parkinson's disease.

Authors:  Beate Winner; Daniela M Vogt-Weisenhorn; Chichung D Lie; Ingmar Blümcke; Jürgen Winkler
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

Review 4.  G-protein-coupled receptors in adult neurogenesis.

Authors:  Van A Doze; Dianne M Perez
Journal:  Pharmacol Rev       Date:  2012-05-18       Impact factor: 25.468

Review 5.  Adult hippocampal neurogenesis: regulation, functional implications, and contribution to disease pathology.

Authors:  Darrick T Balu; Irwin Lucki
Journal:  Neurosci Biobehav Rev       Date:  2008-08-19       Impact factor: 8.989

6.  Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain.

Authors:  Zhude Tu; Shihong Li; Jinbin Xu; Wenhua Chu; Lynne A Jones; Robert R Luedtke; Robert H Mach
Journal:  Nucl Med Biol       Date:  2011-03-03       Impact factor: 2.408

7.  Agonist-induced restoration of hippocampal neurogenesis and cognitive improvement in a model of cholinergic denervation.

Authors:  Jackalina M Van Kampen; Christopher B Eckman
Journal:  Neuropharmacology       Date:  2009-12-22       Impact factor: 5.250

8.  Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurotox Res       Date:  2009-07-16       Impact factor: 3.911

9.  Methamphetamine induces low levels of neurogenesis in striatal neuron subpopulations and differential motor performance.

Authors:  I K Tulloch; L Afanador; L Baker; D Ordonez; H Payne; I Mexhitaj; E Olivares; A Chowdhury; J A Angulo
Journal:  Neurotox Res       Date:  2014-02-19       Impact factor: 3.911

Review 10.  Dopaminergic agonists: possible neurorescue drugs endowed with independent and synergistic multisites of action.

Authors:  Daniela Uberti; Irene Bianchi; Luca Olivari; Giulia Ferrari-Toninelli; Sara A Bonini; Maurizio Memo
Journal:  Neurochem Res       Date:  2007-05-08       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.